Analysts Anticipate Zynerba Pharmaceuticals (ZYNE) to Post -$0.74 EPS

Equities analysts forecast that Zynerba Pharmaceuticals (NASDAQ:ZYNE) will announce earnings of ($0.74) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings, with estimates ranging from ($0.84) to ($0.66). Zynerba Pharmaceuticals reported earnings of ($0.64) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 15.6%. The firm is expected to report its next quarterly earnings report on Tuesday, August 7th.

On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.93) per share for the current financial year, with EPS estimates ranging from ($3.38) to ($2.57). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.66) per share, with EPS estimates ranging from ($3.12) to ($2.36). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.23).

Several research firms have weighed in on ZYNE. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Zynerba Pharmaceuticals in a research report on Thursday, February 1st. Ladenburg Thalmann assumed coverage on shares of Zynerba Pharmaceuticals in a report on Monday, January 29th. They set a “buy” rating and a $25.50 target price for the company. Seaport Global Securities assumed coverage on shares of Zynerba Pharmaceuticals in a report on Friday, January 26th. They set a “buy” rating and a $16.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Zynerba Pharmaceuticals in a report on Monday, March 5th. They set a “buy” rating and a $17.00 target price for the company. Finally, ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals has a consensus rating of “Buy” and an average target price of $17.86.

In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp bought 15,000 shares of the stock in a transaction dated Wednesday, May 2nd. The stock was purchased at an average cost of $10.46 per share, for a total transaction of $156,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.67% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in Zynerba Pharmaceuticals by 385.6% in the 1st quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock worth $106,000 after acquiring an additional 9,701 shares during the last quarter. Alliancebernstein L.P. purchased a new position in Zynerba Pharmaceuticals in the 4th quarter worth approximately $264,000. Wells Fargo & Company MN raised its holdings in Zynerba Pharmaceuticals by 3,759.5% in the 3rd quarter. Wells Fargo & Company MN now owns 34,079 shares of the company’s stock worth $285,000 after acquiring an additional 33,196 shares during the last quarter. Alps Advisors Inc. raised its holdings in Zynerba Pharmaceuticals by 142.1% in the 1st quarter. Alps Advisors Inc. now owns 36,356 shares of the company’s stock worth $316,000 after acquiring an additional 21,337 shares during the last quarter. Finally, A.R.T. Advisors LLC raised its holdings in Zynerba Pharmaceuticals by 33.7% in the 1st quarter. A.R.T. Advisors LLC now owns 86,877 shares of the company’s stock worth $754,000 after acquiring an additional 21,879 shares during the last quarter. Institutional investors own 28.94% of the company’s stock.

Zynerba Pharmaceuticals traded up $0.47, hitting $10.28, during trading hours on Monday, MarketBeat reports. 286,248 shares of the stock traded hands, compared to its average volume of 222,113. The stock has a market cap of $133.04 million, a price-to-earnings ratio of -4.15 and a beta of 4.87. Zynerba Pharmaceuticals has a one year low of $5.42 and a one year high of $20.73.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply